On the agriculture side, IAM just published this week some basic quantitative data analytics spotting DuPont as the leader in CRISPR patent assets. The IAM interview also highlighted some questions about the licensing position of DuPont in the CRISPR patent battle. This was quite surprising to read for us as this information has been publicly known since 2014 and regularly compiled in both our patent and licensing landscapes. Let’s take a closer scrutiny into the DuPont CRISPR assets. In our monitoring of licensing data since 2014, we have actually spotted DuPont Pioneer as one of the earliest player to position their licensing-in in a very strategic way:
The CRISPR patent landscape keeps on steadily growing, with an additional 70 patent publications last month. We have now monitored more than 1400 patent families in our latest CRISPR patent analytics data set. In the past few weeks, our patent landscape data was quoted in the WIPO magazine coverage of CRISPR, while our expert Fabien Palazzoli had the opportunity to present his latest findings at the Cell Line Development and Engineering conference in Amsterdam and to Deftech in Switzerland.
The CRISPR patent landscape keeps on developing at an increasing pace in 2017, with now up to three new patent families published every day! We have searched, reviewed and categorized more than 1146 patent families, now surveyed in our just released 2017 CRISPR patent landscape report.